Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M
Shots:
- Relmada acquired the Sepranolone from Asarina for $3.12M via an asset purchase agreement to develop it as a potential treatment for Tourette syndrome (TS) & other compulsive disorders
- Sepranolone (10mg, BIW, SC) is a GABAA-modulating steroid antagonist that is being investigated in a P-IIa trial, assessing it with SoC vs SoC alone in TS pts (n=26) for 12wks.
- Trial met its 1EP of 28% tic severity reduction (measured by YGTSS), alongside its 2EPs of 69% greater quality of life improvement (GTS-QOL), 50% greater impairment reduction (YGTSS), & 44% greater reduction in the premonitory urge to tic (PUTS) with no CNS off-target effects
Ref: Relmada Therapeutics | Image: Relmada Therapeutics
Related News:- Relmada Therapeutics Reported Results for REL-1017 in the P-III Trial for the Treatment of Major Depressive Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
